In determining the outcomes for Executive KMP, the Board reviewed the quality of earnings and risk management outcomes across the year to ensure STI outcomes were appropriately aligned with the overall performance of the company and the experience of CSL’s shareholders. In consideration of one-off items not anticipated at the time of target setting, the Board’s review resulted in a downward adjustment to the NPATA outcome and an upwards adjustment to the CFO outcome. Overall, this resulted in an average reduction in KMP STI outcomes by 4.1%. The Leading and Managing Modifier was not used in 2023. The Board made no adjustments under the Malus and Clawback Policy and no risk management, behaviour or compliance issues involving Executive KMP were identified during the joint consultation between the HRRC and ARMC. The following performance outcomes were achieved resulting in an average overall STI payment outcome of 102% of target level opportunity across the Executive KMP (see Table 4). The minimum STI earned as a percentage of target level opportunity was 101% and the maximumwas 105% – the latter was 53% of the maximum STI outcome that could be achieved. Table 3 summarises the achievements on the individual KPIs of the Executive KMP. Additional KPIs, which were also integral to the achievement of individual performance, were considered by the Board when assessing Executive KMP performance and remain confidential for commercial reasons. Table 3: Achievements in 2023 Measure and Commentary Threshold 50% Target 100% Maximum 200% CSL Group Outcomes NPATA • NPATA outcome at target 100% CFO • CFO outcome slightly below target 90% Sustainability • Maximum Sustainability outcome 200% Individual Outcomes P McKenzie 95% J Linton 109% P Perreault 95% People • Improvement in safety metrics • Succession planning milestones met • Strong progress against the 2023 diversity, inclusion and equity targets furthering progress to attainment of FY25 and FY30 goals • For the second year in a row CSL was ranked among the best employers in America, according to Forbes and Statista Innovation • First patient dosed with FDA approved HEMGENIX® in the US, the first gene therapy for haemophilia B • Ongoing disciplined management of the R&D pipeline of new products from clinical development to Phase III • Global collaboration and licence agreement signed with Arcturus Therapeutics for access to late-stage next generation mRNA platform technology • New state-of-the-art research and development centres opened in Marburg, Germany and Waltham, United States • CSL’s new Global Headquarters and Centre for R&D opened in Melbourne, Australia Focus • Integration of CSL Vifor and cost synergies on track Efficiency and Reliable Supply • 12 new plasma collection centres opened • Successful reopening of US border centres • Strong growth in plasma collections but Cost per Litre slightly below target • Delay in the plasmapheresis platform rollout • Manufacturing yield improvements above targets set • Capacity and capital expansion projects on target Digital Transformation • Transformation of the CSL Plasma App resulting in much higher usage by donors • Ongoing maturing of cyber resiliency and capability CSL Limited Annual Report 2022/23 97
RkJQdWJsaXNoZXIy MjE2NDg3